A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Long-term therapy: Designed for ongoing use, not a short-term cycle. Supervision required: As a clinical-stage drug, dosing outside trials is not standardized and should be overseen by medical professionals
Work with a licensed healthcare provider for proper medical oversight
Description: This professional-strength liposomal formula from Quicksilver Scientific combines BPC-157 and TB-500 peptides in a highly bioavailable format to support tissue repair, recovery, and overall resilience.* Designed for advanced cellular support, this formula helps maintain optimal joint, gut, and muscle health while promoting systemic healing responses.*
Lets see what this is actually going to do
Batch-coded, COA-supported and supplied strictly for research use only
